(STRUCTURE AND DRUG SCREENING) In the previous CCSG renewal, Structural Biology (SB) and High-Throughput Screening (HTS) were both approved and funded as new Shared Resources (SRs). During the project period, the independent SRs frequently coordinated services for University of Michigan Comprehensive Cancer Center (UMCCC) members to increase the efficiency and impact of cancer-related projects. This collaboration demonstrated the benefit of working together from project initiation. The SRs and UMCCC leaders viewed the amalgamation of the SR as a natural progression and a way for members to receive maximum benefit from these vital resources. With support from UMCCC Senior Leadership, Janet Smith, PhD was joined by Co-Director Vince Groppi, PhD in 2015 when they formally merged the SRs into one unit. During this process, Medicinal Chemistry (MC) was added to the SR to meet existing needs of cancer researchers. In 2016, UMCCC approved the establishment of a comprehensive unified facility, the Structure and Drug Screening (SDS) SR. The SDS SR enables UMCCC members to use advanced structure-based drug design and/or nonbiased HTS strategies to identify chemical matter that can be advanced through a milestone-driven research plan resulting in efficient and effective discovery and development of precision oncology medicines; a strategic goal of UMCCC. This is accomplished by use of three service disciplines, each of which is guided by an experienced faculty leader: SB, under the direction of Dr. Smith; HTS, under the direction of Dr. Groppi, and MC under the direction of Andrew White, PhD. The SR's cohesive activities, services and processes yield four key benefits to UMCCC members: I) projects are advanced along the translational pipeline, from basic science discoveries into early cancer drug discovery; II) a project manager guides researchers in the effective and efficient use of appropriate services matched to their needs; III) an integrated team approach provides researchers a complete, `one-stop' set of expertise for the duration of their projects; and IV) researchers accrue cost savings from a streamlined administrative support structure.
| Dame, Michael K; Attili, Durga; McClintock, Shannon D et al. (2018) Identification, isolation and characterization of human LGR5-positive colon adenoma cells. Development 145: |
| Wang, Qing; Yan, Ran; Pinnell, Nancy et al. (2018) Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development. Blood 132:1279-1292 |
| Owen, Daniel Rocky; Boonstra, Phillip S; Viglianti, Benjamin L et al. (2018) Modeling Patient-Specific Dose-Function Response for Enhanced Characterization of Personalized Functional Damage. Int J Radiat Oncol Biol Phys 102:1265-1275 |
| Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266 |
| Abel, Ethan V; Goto, Masashi; Magnuson, Brian et al. (2018) HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife 7: |
| Srinivasan, Sharan R; Cesa, Laura C; Li, Xiaokai et al. (2018) Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cascades. Mol Cancer Res 16:58-68 |
| Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224 |
| Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757 |
| Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224 |
| Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820 |
Showing the most recent 10 out of 1493 publications
